Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.850
-0.090 (-4.64%)
At close: Apr 2, 2026, 4:00 PM EDT
1.950
+0.100 (5.41%)
After-hours: Apr 2, 2026, 7:56 PM EDT
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$806,444
Market Cap
78.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 25 | -7 | -21.88% | 23 | 2 |
| Dec 31, 2023 | 32 | 1 | 3.23% | 29 | 3 |
| Dec 31, 2022 | 31 | 2 | 6.90% | 28 | 3 |
| Dec 31, 2021 | 29 | 15 | 107.14% | 25 | 4 |
| Dec 31, 2020 | 14 | 10 | 250.00% | 11 | 3 |
| Sep 30, 2020 | 12 | 8 | 200.00% | 9 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Inovio Pharmaceuticals | 112 |
| Adicet Bio | 102 |
| Fortress Biotech | 101 |
| aTyr Pharma | 60 |
| eXoZymes | 31 |
| Cognition Therapeutics | 28 |
| NeurAxis | 21 |
GANX News
- 7 days ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Gain Therapeutics to Present at the 38th Annual ROTH Conference - GlobeNewsWire
- 15 days ago - Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 - GlobeNewsWire
- 21 days ago - Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - GlobeNewsWire
- 3 months ago - Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - GlobeNewsWire
- 3 months ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire